Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction
B Stanek, B Frey, M Hülsmann, R Berger… - Journal of the American …, 2001 - jacc.org
B Stanek, B Frey, M Hülsmann, R Berger, B Sturm, J Strametz-Juranek, J Bergler-Klein…
Journal of the American College of Cardiology, 2001•jacc.orgOBJECTIVES The study assessed the relative predictive potency of neurohumoral factors in
patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking
therapy. BACKGROUND The course of heart failure is characterized by progressive LV
deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly
extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels. METHODS
Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients …
patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking
therapy. BACKGROUND The course of heart failure is characterized by progressive LV
deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly
extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels. METHODS
Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients …
Abstract
OBJECTIVES
The study assessed the relative predictive potency of neurohumoral factors in patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking therapy.
BACKGROUND
The course of heart failure is characterized by progressive LV deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels.
METHODS
Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo. After the double-blind study phase, patients were followed up to four years. Stepwise multivariate regression analyses were performed with 10 variables (age, etiology, LVEF, symptom class, atenolol/placebo, norepinephrine, big ET, log aminoterminal atrial natriuretic peptide, log aminoterminal B-type natriuretic peptide [N-BNP] and log B-type natriuretic peptide [BNP]). During the study, the last values prior to patient death were used, and in survivors the last hormone level, New York Heart Association class and LVEF at month 24 were used.
RESULTS
Thirty-one patients died from a cardiovascular cause during follow-up. At baseline, log BNP plasma level (x2= 13.9, p = 0.0002), treatment allocation (x2= 9.5, p = 0.002) and LVEF (x2= 5.6, p = 0.017) were independently related to mortality. During the study, log BNP plasma level (x2= 21.3, p = 0.0001) remained the strongest predictive marker, with LVEF (x2= 11.2, p = 0.0008) log N-BNP plasma level (x2= 8.9, p = 0.0027) and treatment allocation (x2= 6.4, p = 0.0109) providing additional independent information.
CONCLUSIONS
In patients with advanced LV dysfunction receiving high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy BNP and N-BNP plasma levels are both independently related to mortality. This observation highlights the importance of these hormones and implies that they will likely emerge as a very useful blood test for detection of the progression of heart failure, even in the face of neurohumoral blocking therapy.
jacc.org